MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Longeveron Total Current Liabilities 2011-2026 | LGVN
Annual Total Current Liabilities Longeveron
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.58 M | 3.89 M | 4.87 M | 2.71 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.87 M | 2.58 M | 3.51 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apellis Pharmaceuticals
APLS
|
324 M | $ 20.36 | -1.64 % | $ 2.57 B |  USA |
 |
Aptorum Group Limited
APM
|
4.34 M | $ 0.81 | -4.23 % | $ 4.42 M |  China |
 |
Axsome Therapeutics
AXSM
|
379 M | $ 164.64 | -1.05 % | $ 8.19 B | USA |
 |
I-Mab
IMAB
|
576 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | USA |
 |
AbCellera Biologics
ABCL
|
64.3 M | $ 3.7 | -3.27 % | $ 1.11 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
6.87 M | $ 18.0 | 0.61 % | $ 864 M | USA |
 |
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - |  Russia |
 |
Certara
CERT
|
153 M | $ 7.28 | 3.19 % | $ 1.17 B | USA |
 |
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
58 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
31.3 M | $ 26.28 | -2.16 % | $ 704 M | USA |
 |
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
23.6 M | $ 1.01 | -0.49 % | $ 74.1 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
147 M | $ 23.89 | 0.04 % | $ 2.92 B | USA |
 |
AgeX Therapeutics
AGE
|
5.91 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
3.78 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
256 M | $ 3.22 | -3.59 % | $ 1.15 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
82.2 M | $ 28.92 | -0.96 % | $ 1.68 B | USA |
 |
Champions Oncology
CSBR
|
23.9 M | $ 5.98 | -1.48 % | $ 81.7 M | USA |
 |
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | USA |
 |
Завод ДИОД
DIOD
|
105 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
1.02 B | - | - | - | Russia |
 |
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | USA |
 |
Alector
ALEC
|
69.5 M | $ 2.13 | -3.62 % | $ 219 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
45.2 M | $ 15.77 | -1.81 % | $ 783 M |  Britain |
 |
Allena Pharmaceuticals
ALNA
|
15.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
5.75 M | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
10.5 M | $ 4.25 | 2.04 % | $ 302 M | USA |
 |
Teligent, Inc.
TLGT
|
23.1 M | - | -13.85 % | $ 16.1 M | USA |
 |
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
46 M | - | - | $ 2.91 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Amarin Corporation plc
AMRN
|
194 M | $ 14.2 | 1.9 % | $ 5.89 B |  Irlanda |